Safety and Effectiveness of Adalimumab (HUMIRA) in Patients Diagnosed With Rheumatoid Arthritis (DALI Study).

Trial Profile

Safety and Effectiveness of Adalimumab (HUMIRA) in Patients Diagnosed With Rheumatoid Arthritis (DALI Study).

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2011

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms DALI
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 30 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Aug 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 06 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top